Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Alzheimer disease

Hippocampal volume loss and Alzheimer disease progression

The progression of Alzheimer disease might be monitored by measuring the rate of hippocampal volume loss by means of MRI. Research suggests that a reduction in hippocampal volume can be detected over a period as short as 6 months, and that such volume loss is associated with cognitive decline and other indicators of Alzheimer disease neuropathology.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Henneman, W. J. et al. Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology 72, 999–1007 (2009).

    Article  CAS  Google Scholar 

  2. Schuff, N. et al. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain 132, 1067–1077 (2009).

    Article  CAS  Google Scholar 

  3. Barnes, J. et al. A meta-analysis of hippocampal atrophy rates in Alzheimer's disease. Neurobiol. Aging doi:10.1016/j.neurobiolaging.2008.01.010.

    Article  Google Scholar 

  4. Raber, J., Huang, Y. & Ashford, J. W. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol. Aging 25, 641–650 (2004).

    Article  CAS  Google Scholar 

  5. van de Pol, L. A. et al. Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. Neurology 69, 1491–1497 (2007).

    Article  CAS  Google Scholar 

  6. van der Vlies, A. E. et al. Most rapid cognitive decline in APOEε4 negative Alzheimer's disease with early onset. Psychol. Med. doi:10.1017/S0033291709005492

    Article  CAS  Google Scholar 

  7. Hansson, O. et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5, 228–234 (2006).

    Article  CAS  Google Scholar 

  8. Verwey, N. A. et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann. Clin. Biochem. 46, 235–240 (2009).

    Article  CAS  Google Scholar 

  9. Olsson, A. et al. Simultaneous measurement of β-amyloid(1–42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem. 51, 336–345 (2005).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Wiesje M. van der Flier.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

van der Flier, W., Scheltens, P. Hippocampal volume loss and Alzheimer disease progression. Nat Rev Neurol 5, 361–362 (2009). https://doi.org/10.1038/nrneurol.2009.94

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2009.94

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing